Neuropsychiatric Risks of Anti-Seizure Medications

<p>This <strong>systematic review and meta-analysis</strong> evaluates the connection between <strong>anti-seizure medications (ASMs)</strong> and <strong>neuropsychiatric adverse events</strong> in patients with epilepsy. By analyzing 18 observational studies, researchers examined how different <strong>drug generations</strong> impact <strong>mental health</strong>, focusing on side effects like <strong>depression, psychosis, and cognitive impairment</strong>. The findings indicate that while <strong>first-generation drugs</strong> often correlate with <strong>memory issues</strong>, certain <strong>newer medications</strong> like <strong>topiramate and levetiracetam</strong> show stronger links to <strong>psychosis and suicidality</strong>. Ultimately, the authors conclude that <strong>psychiatric risks</strong> vary significantly across individual treatments, necessitating <strong>routine monitoring</strong> and <strong>personalized selection</strong> of medications. Despite these insights, the study notes that <strong>observational data</strong> and <strong>clinical differences</strong> between patients limit the ability to establish definitive causal relationships.</p>